Related Experiment Video
Updated: May 11, 2026
07:13
Orienteering as a Tool for Cognitive Research: An Implementation Guide
Published on: November 29, 2024
Improving memory in Parkinson's disease: a healthy brain ageing cognitive training program.
Sharon L Naismith1, Loren Mowszowski, Keri Diamond
1Healthy Brain Ageing Clinic, Brain & Mind Research Institute, The University of Sydney, Camperdown, Australia. sharon.naismith@sydney.edu.au
Summary
This cognitive training program improved memory and learning in Parkinson's disease patients. The intervention also increased awareness of cognitive strategies and risk factors for brain health.
Area of Science:
- Neuroscience
- Gerontology
- Cognitive Psychology
Background:
- Parkinson's disease (PD) is associated with cognitive decline, impacting memory and learning.
- A 'healthy brain ageing' approach may offer benefits for cognitive function in PD patients.
- Existing interventions often lack a multifactorial approach targeting various cognitive and lifestyle factors.
Purpose of the Study:
- To evaluate the efficacy of a multifactorial cognitive training program for individuals with Parkinson's disease.
- To assess improvements in memory, other cognitive domains, and knowledge related to brain health.
- To explore the program's potential in slowing cognitive decline and enhancing adaptive strategies.
Main Methods:
- A single-blinded, waitlist control design was employed with 50 participants diagnosed with Parkinson's disease.
- The intervention consisted of a 7-week program with twice-weekly 2-hour group sessions.
- Sessions included psychoeducation on lifestyle factors and computer-based cognitive training delivered by health professionals and neuropsychologists.
Main Results:
- Significant improvements in learning and memory were observed, with medium to large effect sizes.
- Participants showed medium effect size improvements in knowledge of psychoeducation material.
- The program successfully increased awareness of cognitive strategies and modifiable risk factors.
Conclusions:
- A multifactorial 'healthy brain ageing' cognitive training program shows promise for improving memory in Parkinson's disease.
- The intervention may serve as a viable tool to potentially slow cognitive decline in the PD population.
- The program enhanced participants' understanding of adaptive cognitive strategies and lifestyle modifications for brain health.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:30Cognitive Development During Adulthood
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...